Please enable JS

Investors & Media

News Releases

Date Title  
09/20/18 CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares Printer Friendly Version
09/19/18 CRISPR Therapeutics Announces Proposed Public Offering of Common Shares Printer Friendly Version
09/17/18 CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes Printer Friendly Version
09/10/18 CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology Printer Friendly Version
08/30/18 CRISPR Therapeutics to Present at Upcoming Investor Conferences Printer Friendly Version
08/07/18 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results Printer Friendly Version
06/19/18 CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing Printer Friendly Version
06/05/18 CRISPR Therapeutics to Participate in Three June Conferences Printer Friendly Version
05/30/18 CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease Printer Friendly Version
05/15/18 CRISPR Therapeutics Announces Presentations at the ASGCT 21st Annual Meeting Printer Friendly Version
05/08/18 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2018 Financial Results Printer Friendly Version
05/03/18 CRISPR Therapeutics to Participate in May Investor Conferences Printer Friendly Version
04/16/18 CRISPR Therapeutics Presents Positive Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018 Printer Friendly Version
04/13/18 CRISPR Therapeutics to Present Data on Allogeneic CRISPR-based CAR-T Cell Therapies at AACR 2018 Printer Friendly Version
04/04/18 CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs Printer Friendly Version
03/26/18 CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property Printer Friendly Version
03/08/18 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results Printer Friendly Version
02/21/18 CRISPR Therapeutics to Participate in Four Upcoming Investor Conferences Printer Friendly Version
02/08/18 CRISPR Therapeutics Announces Transition of Bill Lundberg, MD Printer Friendly Version
01/04/18 CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares Printer Friendly Version
01/03/18 CRISPR Therapeutics Announces Proposed Public Offering of Common Shares Printer Friendly Version
Print Page RSS Feeds E-mail Alerts IR Contacts